Intra Abdominal Infection Market Research Report: Market size, Industry outlook, Market Forecast, Demand Analysis,Market Share, Market Report 2018-2023
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Intra Abdominal Infection Market
Intra Abdominal Infection Market: By Causing Agents (E. coli, Streptococci, Enterococci, Klebsiella, Pseudomonas, H. pylori), By Diagnosis (Blood Tests, Abdominal X-Ray, Computed Tomography (Ct), Ultrasound), By Drugs, By Geography - Forecast(2018 - 2023)
Report Code : HCR 0232
Updated Date: 16 May, 2018  

1. Intra-Abdominal Infection – Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Intra-Abdominal Infection – Market Forces
   4.1. Drivers
      4.1.1. Increasing awareness and medical infrastructure in the developing nation
   4.2. Restraints
      4.2.1. The disease is difficult to diagnose and treat due to involvement of large number of causative agents, poor prognosis and varied symptoms
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Intra-Abdominal Infection – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Intra Abdominal Infection  Market, By  Causing Agents
   6.1. E. coli
   6.2. Streptococci
   6.3. Enterococci
   6.4. Klebsiella
   6.5. Pseudomonas
   6.6. H. pylori
7. Intra Abdominal Infection  Market, By Diagnosis
   7.1. Blood Tests
   7.2. Abdominal X-Ray
   7.3. Computed Tomography (Ct)
   7.4. Ultrasound
8. Intra Abdominal Infection  Market, By Drugs
   8.1. Anaerobic coverage
      8.1.1. Metronidazole
      8.1.2. Clindamycin
      8.1.3. Chloramphenicol
   8.2. Aerobic coveragee
      8.2.1. Beta lactums
            8.2.1.1. Cefotaxin
            8.2.1.2. Ceftriaxone
            8.2.1.3. Aztreonam
      8.2.2. Quinolones
            8.2.2.1. Ciprofloxacine
            8.2.2.2. Livofloxacine
      8.2.3. Aminoglycosides
            8.2.3.1. Gentamycine
            8.2.3.2. Tobramycine
   8.3. Vancomycines
9. Intra Abdominal Infection  Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Intra Abdominal Infection – Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   11.1. Pfizer Inc.
   11.2. Merck Sharp & Dohme Corp.
   11.3. Tetraphase Pharmaceuticals
   11.4. AstraZeneca PLC
   11.5. Merck & Co., Inc.
   11.6. Atox Bio Inc
   11.7. Aurobindo Pharma Ltd.
   11.8. Teva
   11.9. Dr Reddys Labs Ltd.
   11.10. Bayer AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll